New drug combo for newly diagnosed AL amyloidosis
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two new drugs, sonrotoclax and a BCMA bispecific antibody, for people newly diagnosed with AL amyloidosis. The treatment aims to target and destroy the abnormal cells that cause the disease, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been newly diagnosed with AL amyloidosis and have not yet received treatment for it.
- You have a specific genetic change called t(11;14) (for the first part of the study).
- Your heart, liver, and kidneys are functioning adequately.
- Your blood counts are within acceptable levels.
- You are willing to use effective contraception if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.